Partner Therapeutics begins clinical trials for Leukine in Singapore
Category: #headline  By Pranali Mehta  Date: 2020-05-30
  • share
  • Twitter
  • Facebook
  • LinkedIn
Partner Therapeutics begins clinical trials for Leukine in Singapore

 

  • The trials are being conducted to test the effects of Leukine on respiratory failure due to COVID 19.
  • The drug has already been under clinical trials for COVID 19 since March when they started testing in 5 hospitals in Belgium. 

The commercial biotech company, Partner Therapeutics has announced the initiation of clinical trials for its drug Leukine. This will be a randomized, placebo-controlled, double-blind study for patients with acute respiratory illness related to COVID 19. This study will be conducted at Singapore General Hospital and will detect the effects of Leukine on respiratory lung function.

Prof. Jenny Guek Hong Law, Senior consultant for the Department of Infectious Diseases at the Singapore General Hospital revealed that there is sufficient data to understand that GM-CSF plays an important role in lung health and emerging data points to the fact that the initial evolution of the disease is now being steered by the deficiency of Alveolar macrophages and GM-CSF. She also expressed an eagerness to advance this research in the weeks ahead because of the increasing morbidity rate due to COVID 19. 

Patients suffering from acute hypoxic respiratory failure due to COVID 19 are liable to be a part of the study. Patients will receive doses of intravenous Leukine for 5 days apart for the local standard of care. By evaluating the difference in oxygenation measures, the study will test the effect of Leukine on lung homeostasis.

The study is being conducted under SARPAC (Sargramostim in patients with acute respiratory failure due to COVID 19) which is the first randomized study to the effects of Leukine in the treatment of COVID 19 and is now nearing completion. Partner Therapeutics had previously announced that clinical trials for Leukine were underway in 5 Belgian hospitals to treat patients suffering from respiratory illness due to COVID 19.

Dr. Debasish Roychowdhury, the Chief Medical Officer at Partner Therapeutics reportedly stated that GM-CSF is of critical importance for normal lung function and that COVID 19 damages the components of lung most dependent on GM-CSF. He also said that the number of testimonies now coming out and revealing the importance of GM-CSF upon investigation to boost the immune system and repair the lung is a validation of their rationale. 

Leukine received FDA approval back in 1991 after establishing a safety profile treating 500,000 patients, but the effectiveness of the drug in the treatment of respiratory illness due to COVID 19 is still under investigation and has not yet been fully established.

Source Credits: https://www.partnertx.com/partner-therapeutics-announces-initiation-of-clinical-trial-to-evaluate-leukine-in-respiratory-illness-in-patients-with-covid-19-at-singapore-general-hospital/

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Pranali Mehta    

Pranali Mehta

Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali deci...

Read More >>

More News By Pranali Mehta

Trees Corporation to acquire Green Tree assets to expand its footprint
Trees Corporation to acquire Green Tree assets to expand its footprint
By Pranali Mehta

Cannabis Company, TREES CORPORATION, is delighted to announce that it has entered into a definitive agreement to take over the Green Tree Berthoud and Green Tree Longmont dispensaries in the Colorado state, around 34,000 Sq. Ft of grow operations and...

Larsen & Toubro Infotech extends partnership with Google Cloud
Larsen & Toubro Infotech extends partnership with Google Cloud
By Pranali Mehta

Larsen & Toubro Infotech (LTI), an Indian information technology services conglomerate, has expanded its partnership with Google Cloud. According to sources, LTI is planning to build a dedicated unit of business for six key solution pillars of Go...

JetBlue eyeing hostile takeover of low-cost carrier Spirit Airlines
JetBlue eyeing hostile takeover of low-cost carrier Spirit Airlines
By Pranali Mehta

JetBlue Airways has reportedly filed a hostile takeover attempt for Spirit Airlines after the low-cost carrier rejected a USD 3.6 billion acquisition deal to merge with Frontier Airlines. JetBlue, which had offered USD 30 per share to Spirit Airline...